Skip to main content

Single-fraction Radiation Treatment Dose Response in a Genetically Engineered Mouse Model of Medulloblastoma.

Publication ,  Journal Article
Tu, KJ; Stewart, CE; Williams, NT; Ma, Y; Luo, L; Ghosh, D; Weidenhammer, LB; Floyd, SR; Fan, Y; Kirsch, DG; Oldham, M; Reitman, ZJ
Published in: Radiat Res
December 1, 2023

Medulloblastoma is the most common malignant brain tumor of children. Although standard of care radiotherapy for pediatric medulloblastoma (PM) can lead to long-term remission or cure in many patients, it can also cause life-long cognitive impairment and other adverse effects. The pathophysiological mechanisms involved in radiation-induced cerebral damage are incompletely understood, and their elucidation may lead to interventions that mitigate radiation toxicity. To explore the mechanisms of radiation-induced cerebral damage, transgenic mouse models of PM and non-tumor-bearing controls were exposed to radiation doses that ranged from 0 to 30 Gy. Between 0-20 Gy, a significant dose-dependent reduction in tumor-associated hydrocephalus and increase in overall survival were observed. However, at 30 Gy, hydrocephalus incidence increased and median overall survival fell to near-untreated levels. Immunohistochemistry revealed that both tumor-bearing and non-tumor-bearing mice treated with 30 Gy of radiation had significantly more reactive astrocytes and microvascular damage compared to untreated controls. This effect was persistent across mice that were given 1 and 2 weeks of recovery time after irradiation. Our data suggest that radiation therapy promotes neural death by inducing long-term neuroinflammation in PM, suggesting radiation delivery methods that limit inflammation may be effective at widening the therapeutic window of radiation therapy in PM patients.

Duke Scholars

Published In

Radiat Res

DOI

EISSN

1938-5404

Publication Date

December 1, 2023

Volume

200

Issue

6

Start / End Page

587 / 592

Location

United States

Related Subject Headings

  • Radiation Injuries
  • Oncology & Carcinogenesis
  • Mice
  • Medulloblastoma
  • Hydrocephalus
  • Humans
  • Child
  • Cerebellar Neoplasms
  • Brain Neoplasms
  • Animals
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tu, K. J., Stewart, C. E., Williams, N. T., Ma, Y., Luo, L., Ghosh, D., … Reitman, Z. J. (2023). Single-fraction Radiation Treatment Dose Response in a Genetically Engineered Mouse Model of Medulloblastoma. Radiat Res, 200(6), 587–592. https://doi.org/10.1667/RADE-23-00126.1
Tu, Kevin J., Connor E. Stewart, Nerissa T. Williams, Yan Ma, Lixia Luo, Debosir Ghosh, Loren B. Weidenhammer, et al. “Single-fraction Radiation Treatment Dose Response in a Genetically Engineered Mouse Model of Medulloblastoma.Radiat Res 200, no. 6 (December 1, 2023): 587–92. https://doi.org/10.1667/RADE-23-00126.1.
Tu KJ, Stewart CE, Williams NT, Ma Y, Luo L, Ghosh D, et al. Single-fraction Radiation Treatment Dose Response in a Genetically Engineered Mouse Model of Medulloblastoma. Radiat Res. 2023 Dec 1;200(6):587–92.
Tu, Kevin J., et al. “Single-fraction Radiation Treatment Dose Response in a Genetically Engineered Mouse Model of Medulloblastoma.Radiat Res, vol. 200, no. 6, Dec. 2023, pp. 587–92. Pubmed, doi:10.1667/RADE-23-00126.1.
Tu KJ, Stewart CE, Williams NT, Ma Y, Luo L, Ghosh D, Weidenhammer LB, Floyd SR, Fan Y, Kirsch DG, Oldham M, Reitman ZJ. Single-fraction Radiation Treatment Dose Response in a Genetically Engineered Mouse Model of Medulloblastoma. Radiat Res. 2023 Dec 1;200(6):587–592.

Published In

Radiat Res

DOI

EISSN

1938-5404

Publication Date

December 1, 2023

Volume

200

Issue

6

Start / End Page

587 / 592

Location

United States

Related Subject Headings

  • Radiation Injuries
  • Oncology & Carcinogenesis
  • Mice
  • Medulloblastoma
  • Hydrocephalus
  • Humans
  • Child
  • Cerebellar Neoplasms
  • Brain Neoplasms
  • Animals